(Dec. 2, 2007) Various products of Cuban biotechnology, among these the newly created pentavalent vaccine "Heberpenta," will be at the disposal of commercial associates of Heber Biotec S.A. between 2008 and 2010.
Heber Biotec S.A., which is certified by Norm ISO 9001:2000, is the exclusive representative and commercial corporation [comercializadora] of the Centro de Ingeniería Genética y Biotecnología ([CIGB—in Spanish] Genetic Engineering and Biotechnology Center) and other institutions of the Polo Científico del Oeste de la Habana (Scientific Hub of Western Havana). Heber Biotec S.A holds more than 200 sanitary registries [registros sanitarios], approved in 52 countries, and signed distribution agreements with companies all over the world.
"Heberpenta," which was created through the cooperation of the CIGB, the Finlay Institute (a scientific organization dedicated to vaccine research and production), and the Laboratorio de Reactivos Químicos de la Universidad de La Habana (Chemical Reagent Laboratory of the University of Havana), immunizes against five diseases at once: diphtheria, tetanus; pertussis (whooping cough); hepatitis B; and, Haemophilus influenzae type b (Hib), which causes meningitis, pneumonias and otitis, and is the cause of death of half a million infants in the world.
The vaccines that compose the pentavalent vaccine [vacuna pentavalente, i.e., having a valence of 5] provide protection as follows: 95% for diphtheria and tetanus; 80% for pertussis; 98% for hepatitis B; and, according to clinical studies, 99.7% for Haemophilus influenzae type b (Hib). (Riera, Lilliam, Cuba comercializará al exterior nueva vacuna pentavalente: Heberpenta inmuniza contra la difteria, tétanos, tos ferina, hepatitis B y la bacteria Haemophilus influenzae tipo B, GRANMA INTERNACIONAL DIGITAL, EDICIÓN EN ESPAÑOL, Nov. 30 2007.)